HLA-Bw4 in association with KIR3DL1 favors natural killer cell-mediated protection against severe COVID-19

References

• Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Ballow M, Haga CL. Why do some people develop serious COVID-19 disease after infection, while others only exhibit mild symptoms? J Allergy Clin Immunol Pract. 2021;9(4):1442–1448.
   PubMed Web of Science ®Google Scholar
• Aguiar VRC, Augusto DG, Castelli EC, et al. An immunogenetic view of COVID-19. Genet Mol Biol 2021;44(1 Suppl 1):e20210036.
   PubMed Web of Science ®Google Scholar
• Chen T, Lin YX, Zha Y, et al. A low-producing haplotype of interleukin-6 disrupting CTCF binding is protective against severe COVID-19. mBio. 2021;12(5):e0137221.
   PubMed Web of Science ®Google Scholar
• Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe COVID-19 with respiratory failure. N Engl J Med 2020;383(16):1522–1534.
   PubMed Web of Science ®Google Scholar
• Schetelig J, Heidenreich F, Baldauf H, et al. Individual HLA-a,-b,-c, and-DRB1 genotypes are no major factors which determine COVID-19 severity. Front Immunol. 2021;12:698193.
   PubMed Web of Science ®Google Scholar
• Novelli A, Andreani M, Biancolella M, et al. HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. Hla. 2020;96(5):610–614.
   PubMed Web of Science ®Google Scholar
• Wang F, Huang S, Gao R, et al. Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov. 2020;6(1):83.
   PubMed Web of Science ®Google Scholar
• Shkurnikov M, Nersisyan S, Jankevic T, et al. Association of HLA class I genotypes with severity of coronavirus disease-19. Front Immunol. 2021;12:641900.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang W, Zhang J, et al. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19). Hla. 2020;96(2):194–196.
   PubMed Web of Science ®Google Scholar
• Langton DJ, Bourke SC, Lie BA, et al. The influence of Hla genotype on the severity of COVID-19 infection. Hla. 2021;98(1):14–22.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Bautista JF, Rodriguez-Nicolas A, Rosales-Castillo A, et al. Study of HLA-A,-B,-C,-DRB1 and-DQB1 polymorphisms in COVID-19 patients. J Microbiol Immunol Infection. 2022;55(3):421–427.
   Web of Science ®Google Scholar
• Zhang Y, Chen Y, Li Y, et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι. Proc Natl Acad Sci USA. 2021;118(23):e2024202118.
   PubMed Web of Science ®Google Scholar
• Flower TG, Buffalo CZ, Hooy RM, et al. Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein. Proc Natl Acad Sci USA. 2021;118(2):e2021785118.
   PubMed Web of Science ®Google Scholar
• Winter CC, Gumperz JE, Parham P, et al. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol. 1998;161(2):571–577.
   PubMed Web of Science ®Google Scholar
• Carrington M, Wang S, Martin MP, et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 2005;201(7):1069–1075.
   PubMed Web of Science ®Google Scholar
• Hansasuta P, Dong T, Thananchai H, et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol. 2004;34(6):1673–1679.
   PubMed Web of Science ®Google Scholar
• Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436(7051):709–713.
   PubMed Web of Science ®Google Scholar
• Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol. 2013;31:163–194.
   PubMed Web of Science ®Google Scholar
• Santamaria P, Lindstrom AL, Boyce-Jacino MT, et al. HLA class I sequence-based typing. Hum Immunol. 1993;37(1):39–50.
   PubMed Web of Science ®Google Scholar
• Rajalingam R, Ashouri E. Methods in molecular biology. Methods Mol Biol. 2013;1034:239–255.
   PubMedGoogle Scholar
• Vita R, Mahajan S, Overton JA, et al. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res 2019;47(D1):D339–DD43.
   PubMed Web of Science ®Google Scholar
• Grifoni A, Sidney J, Vita R, et al. SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19. Cell Host Microbe. 2021;29(7):1076–1092.
   PubMed Web of Science ®Google Scholar
• Fischer JC, Schmidt AG, Bolke E, et al. Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19. Eur J Med Res. 2021;26(1):107.
   PubMed Web of Science ®Google Scholar
• Kubo H, Ikeda-Moore Y, Kikuchi A, et al. Residue 116 determines the C-terminal anchor residue of HLA-B * 3501 and -B * 5101 binding peptides but does not explain the general affinity difference. Immunogenetics. 1998;47(3):256–263.
   PubMed Web of Science ®Google Scholar
• Nguyen A, David JK, Maden SK, et al. Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. J Virol. 2020;94(13):e00510-20.
   PubMed Web of Science ®Google Scholar
• Hilton HG, McMurtrey CP, Han AS, et al. The intergenic recombinant HLA-B∗46:01 has a distinctive peptidome that includes KIR2DL3 ligands. Cell Rep. 2017;19(7):1394–1405.
   PubMed Web of Science ®Google Scholar
• Lin M, Tseng HK, Trejaut JA, et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet 2003;4:9.
   PubMedGoogle Scholar
• Horst D, van Leeuwen D, Croft NP, et al. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J Immunol. 2009;182(4):2313–2324.
   PubMed Web of Science ®Google Scholar
• Croft NP, Shannon-Lowe C, Bell AI, et al. Stage-specific inhibition of MHC class I presentation by the epstein-barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog 2009;5(6):e1000490.
   PubMed Web of Science ®Google Scholar
• Zuo J, Currin A, Griffin BD, et al. The epstein-barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog 2009;5(1):e1000255.
   PubMed Web of Science ®Google Scholar
• Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294(1-2):15–22.
   PubMed Web of Science ®Google Scholar
• Deng Z, Zhen J, Harrison GF, et al. Adaptive admixture of HLA class I allotypes enhanced genetically determined strength of natural killer cells in east asians. Mol Biol Evol 2021;38(6):2582–2596.
   PubMed Web of Science ®Google Scholar
• Apps R, Meng Z, Del Prete GQ, et al. Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells. J Immunol. 2015;194(8):3594–3600.
   PubMed Web of Science ®Google Scholar
• Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007;39(6):733–740.
   PubMed Web of Science ®Google Scholar
• Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol. 2013;13(2):133–144.
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Apple RJ, Chen CJ, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 2002;94(23):1780–1789.
   PubMedGoogle Scholar